Literature DB >> 10786684

Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity.

A Gijsens1, L Missiaen, W Merlevede, P de Witte.   

Abstract

Certain tumor cells, such as squamous carcinoma cells, express an increased number of epidermal growth factor (EGF) receptors. Therefore, we studied the targeted delivery of the photocytotoxic compound Sn-(IV)chlorin e6 monoethylenediamine [SnCe6(ED)] to tumors that overexpress the EGF receptor. EGF was conjugated to SnCe6(ED) through a carrier, such as dextran (Dex) and human serum albumin (HSA), and the photocytotoxicity on the EGF receptor-overexpressing MDA-MB-468 breast adenocarcinoma cell line was evaluated. The photobiological activities of these EGF conjugates, of the conjugates of the photosensitizer to HSA or Dex, or of the photosensitizer alone were compared. The affinity of EGF for its receptor was substantially impaired when conjugated in EGF-Dex-SnCe6(ED), in contrast to EGF-HSA-SnCe6(ED). In corresponding results, EGF-HSA-SnCe6(ED) displayed a high photocytotoxicity (IC50, 63 nM) on MDA-MB-468 cells at a light dose of 27 kJ/m2, whereas EGF-Dex-SnCe6(ED) showed very limited photocytotoxicity. EGF-HSA-SnCe6(ED) was no longer photocytotoxic in the presence of a competing EGF concentration. The high photocytotoxicity of EGF-HSA-SnCe6(ED) was shown to be the result of a high intracellular concentration in MDA-MB-468 cells, which could be lowered dramatically by incubating the conjugate with a competing EGF concentration. In contrast, EGF-Dex-SnCe6(ED) accumulated poorly in MDA-MB-468 cells, in agreement with its low EGF receptor affinity and photocytotoxicity. EGF-HSA-SnCe6(ED) produced much more intracellular reactive oxygen species on light irradiation than EGF-Dex-SnCe6(ED). It is concluded that the photodynamic activity of the EGF-HSA conjugate of SnCe6(ED) on MDA-MB-468 breast adenocarcinoma cells is EGF specific and is much more potent than EGF-Dex-SnCe6(ED) or free SnCe6.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10786684

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Photodynamic efficacy of hypericin targeted by two delivery techniques to hepatocellular carcinoma cells.

Authors:  Maha Fadel; Kawser Kassab; Tareq Youssef
Journal:  Lasers Med Sci       Date:  2010-09       Impact factor: 3.161

2.  Efficacy of chlorin e6-mediated sono-photodynamic therapy on 4T1 cells.

Authors:  Qing Li; Xiaobing Wang; Pan Wang; Kun Zhang; Haiping Wang; Xiaolan Feng; Quanhong Liu
Journal:  Cancer Biother Radiopharm       Date:  2013-11-09       Impact factor: 3.099

Review 3.  Targeted photodynamic therapy in head and neck squamous cell carcinoma: heading into the future.

Authors:  Sophie Marchal; Gilles Dolivet; Henri-Pierre Lassalle; François Guillemin; Lina Bezdetnaya
Journal:  Lasers Med Sci       Date:  2015-01-07       Impact factor: 3.161

4.  Bioconjugatable porphyrins bearing a compact swallowtail motif for water solubility.

Authors:  K Eszter Borbas; Pawel Mroz; Michael R Hamblin; Jonathan S Lindsey
Journal:  Bioconjug Chem       Date:  2006 May-Jun       Impact factor: 4.774

5.  Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer.

Authors:  Zhiwei Hu; Benqiang Rao; Shimin Chen; Jinzhong Duanmu
Journal:  Breast Cancer Res Treat       Date:  2010-06-01       Impact factor: 4.872

Review 6.  Breast cancer as photodynamic therapy target: Enhanced therapeutic efficiency by overview of tumor complexity.

Authors:  María Julia Lamberti; Natalia Belén Rumie Vittar; Viviana Alicia Rivarola
Journal:  World J Clin Oncol       Date:  2014-12-10

7.  Porphyrin and galactosyl conjugated micelles for targeting photodynamic therapy.

Authors:  De-Qun Wu; Ze-Yong Li; Cao Li; Jian-Jun Fan; Bo Lu; Cong Chang; Si-Xue Cheng; Xian-Zheng Zhang; Ren-Xi Zhuo
Journal:  Pharm Res       Date:  2009-11-04       Impact factor: 4.200

8.  Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.

Authors:  Shannon M Gallagher-Colombo; Joann Miller; Keith A Cengel; Mary E Putt; Sergei A Vinogradov; Theresa M Busch
Journal:  Cancer Res       Date:  2015-06-08       Impact factor: 12.701

9.  Targeting the EGF receptor for ovarian cancer therapy.

Authors:  Reema Zeineldin; Carolyn Y Muller; M Sharon Stack; Laurie G Hudson
Journal:  J Oncol       Date:  2009-12-28       Impact factor: 4.375

10.  Porphyrins as theranostic agents from prehistoric to modern times.

Authors:  Yumiao Zhang; Jonathan F Lovell
Journal:  Theranostics       Date:  2012-09-30       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.